Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification
- Ou, S. H.
- Kwak, E. L.
- Siwak-Tapp, C.
- Dy, J.
- Bergethon, K.
- Clark, J. W.
- Camidge, D. R.
- Solomon, B. J.
- Maki, R. G.
- Bang, Y. J.
- Kim, D. W.
- Christensen, J.
- Tan, W.
- Wilner, K. D.
- Salgia, R.
- Iafrate, A. J.
Publication date
May 2011
DOI Publisher
Ovid Technologies (Wolters Kluwer Health) ISSN
1556-0864 Citation count (estimate)
280Abstract
Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor
Add to ORKG